Safety and short-term therapeutic effects of miriplatin-lipiodol suspension in transarterial chemoembolization (TACE) for hepatocellular carcinoma

Anticancer Research

Volumn 31, Issue 9, 2011, Pages 2983-2988

  Okabe, Kazutoshi ^a   Beppu, Toru ^c   Haraoka, Katsuki ^b   Oh Uchida, Yoshihiro ^b   Yamamura, Sadahiro ^b   Tomiyasu, Shinjiro ^a   Yamanaka, Tsuyoshi ^a   Sano, Osamu ^a   Masuda, Toshiro ^c   Chikamoto, Akira ^c   Fujiyama, Shigetoshi ^b   Baba, Hideo ^c  

^a NTT West Kyusyu Hospital   (Japan)

^b NTT West Kyushu Hospital   (Japan)

^c KUMAMOTO UNIVERSITY   (Japan)

Author keywords

Hepatocellular carcinoma; Miriplatin; Transarterial chemoembolization

Indexed keywords

ALPHA FETOPROTEIN; FLUOROURACIL; IODINATED POPPYSEED OIL; MIRIPLATIN;

ADULT; AGED; ANAPHYLAXIS; ANOREXIA; ARTICLE; CHEMOEMBOLIZATION; CHEMOTHERAPY INDUCED EMESIS; DIARRHEA; DRUG SAFETY; FATIGUE; FEMALE; FEVER; HUMAN; HYPOTENSION; LABORATORY TEST; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; MORBIDITY; NAUSEA; PAIN; PRIORITY JOURNAL;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; CARCINOMA, HEPATOCELLULAR; CHEMOEMBOLIZATION, THERAPEUTIC; ETHIODIZED OIL; FEMALE; HUMANS; LIVER NEOPLASMS; MALE; MIDDLE AGED; ORGANOPLATINUM COMPOUNDS;

EID: 80051610261     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. Llovet JM, Real MI, Montaña X, Planas R, Coll S, Aponte J, Ayuso C, Sala M, Muchart J, Solà R, Rodés J and Bruix J: Barcelona Liver Cancer Group: Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet 359: 1734-1739, 2002. (Pubitemid 34607087)
2. Llovet JM and Bruix J: Systematic review of randomized trials for unresectable hepatocellular carcinoma: Chemoembolization improves survival. Hepatology 37: 429-442, 2003. (Pubitemid 36152543)
3. Shibata J, Fujiyama S, Sato T, Kishimoto S, Fukushima S and Nakano M: Hepatic arterial injection chemotherapy with cisplatin suspended in an oily lymphographic agent for hepatocellular carcinoma. Cancer 64: 1586-1594, 1989. (Pubitemid 19251124)
4. Beppu T, Ohara C, Yamaguchi Y, Ichihara T, Yamanaka T, Katafuchi S, Ikei S, Mori K, Fukushima S and Nakano M: A new approach to chemoembolization for unresectable hepatocellular carcinoma using aclarubicin microspheres in combination with cisplatin suspended in iodized oil. Cancer 68: 2555-2560, 1991.
5. Ueno K, Miyazono N, Inoue H, Nishida H, Kanetsuki I and Nakajo M: Transcatheter arterial chemoembolization therapy using iodized oil for patients with unresectable hepatocellular carcinoma: evaluation of three kinds of regimens and analysis of prognostic factors. Cancer 88: 1574-1581, 2000. (Pubitemid 30183142)
6. Kamada K, Nakanishi T, Kitamoto M, Aikata H, Kawakami Y, Ito K, Asahara T and Kajiyama G: Long-term prognosis of patients undergoing transcatheter arterial chemoembolization for unresectable hepatocellular carcinoma: comparison of cisplatin-lipiodol suspension and doxorubicin hydrochloride emulsion. J Vasc Interv Radiol 12: 847-854, 2001. (Pubitemid 32642435)
7. Yoshikawa M, Ono N, Yodono H, Ichida T and Nakamura H: Phase II study of hepatic arterial infusion of a fine-powder formulation of cisplatin for advanced hepatocellular carcinoma. Hepatol Res 38: 474-483, 2008. (Pubitemid 351593948)
8. Ikeda M, Maeda S, Ashihara H, Nagahama H, Tanaka M and Sasaki Y: Transcatheter arterial infusion chemotherapy with cisplatin-lipiodol suspension in patients with hepatocellular carcinoma. J Gastroenterol 45: 60-67, 2010.
9. Moriguchi M, Takayama T, Nakamura M, Aramaki O, Higaki T, Nakayama H, Ohkubo T and Fujii M: Phase I/II study of a fine-powder formulation of cisplatin for transcatheter arterial chemoembolization in hepatocellular carcinoma. Hepatol Res 40: 369-375, 2010.
10. Nagamatsu H, Hiraki M, Mizukami N, Yoshida H, Iwamoto H, Sumie S, Torimura T and Sata M: Intra-arterial therapy with cisplatin suspension in lipiodol and 5-fluorouracil for hepatocellular carcinoma with portal vein tumour thrombosis. Aliment Pharmacol Ther 32: 543-550, 2010.
11. Kasai K, Ushio A, Sawara K, Miyamoto Y, Kasai Y, Oikawa K, Kuroda H, Takikawa Y and Suzuki K: Transcatheter arterial chemoembolization with a fine-powder formulation of cisplatin for hepatocellular carcinoma. World J Gastroenterol 16: 3437-3444, 2010.
12. Yodono H, Matsuo K and Shinohara A: A retrospective comparative study of epirubicin-lipiodol emulsion and cisplatin-lipiodol suspension for use with transcatheter arterial chemoembolization for treatment of hepatocellular carcinoma. Anticancer Drugs 22: 277-282, 2011.
13. Kawaoka T, Aikata H, Katamura Y, Takaki S, Waki K, Hiramatsu A, Takahashi S, Hieda M, Kakizawa H and Chayama K: Hypersensitivity reactions to transcatheter chemoembolization with cisplatin and lipiodol suspension for unresectable hepatocellular carcinoma. J Vasc Interv Radiol 21: 1219-1225, 2010.
14. Kishimoto S, Miyazawa K, Terakawa Y, Ashikari H, Ohtani A, Fukushima S and Takeuchi Y: Cytotoxicity of cis-[((1R,2R)-1,2-cyclohexanediamine-N, N′(myristato)]-platinum (II) suspended in lipiodol in a newly established cisplatin-resistant rat hepatoma cell line. Jpn J Cancer Res 91: 1326-1332, 2000. (Pubitemid 32042368)
15. Okusaka T, Okada S, Nakanishi T, Fujiyama S and Kubo Y: Phase II trial of intra-arterial chemotherapy using a novel lipophilic platinum derivative (SM-11355) in patients with hepatocellular carcinoma. Invest New Drugs 22: 169-176, 2004. (Pubitemid 38270472)
16. Hanada M, Baba A, Tsutsumishita Y, Noguchi T and Yamaoka T: Intra-hepatic arterial administration with miriplatin suspended in an oily lymphographic agent inhibits the growth of human hepatoma cells orthotopically implanted in nude rats. Cancer Sci 100: 189-194, 2009.
17. Hanada M, Baba A, Tsutsumishita Y, Noguchi T, Yamaoka T, Chiba N and Nishikaku F: Intra-hepatic arterial administration with miriplatin suspended in an oily lymphographic agent inhibits the growth of tumors implanted in rat livers by inducing platinum-DNA adducts to form and massive apoptosis. Cancer Chemother Pharmacol 64: 473-483, 2009.
18. Ikeda K, Okusaka T, Ikeda M and Morimoto M: Transcatheter arterial chemoembolization with a lipophilic platinum complex SM-11355 (miriplatin hydrate) - safety and efficacy in combination with embolizing agents. Jpn J Cancer Chemother 37: 271-275, 2010 (in Japanese).
19. Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET and Carbone PP: Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 5: 649-655, 1982. (Pubitemid 13149996)
20. Kudo M, Kubo S, Takayasu K, Sakamoto M, Tanaka M, Ikai I, Furuse J, Nakamura K and Makuuchi M; for The Liver Cancer Study Group of Japan: Response Evaluation Criteria in Cancer of the Liver (RECICL) proposed by the Liver Cancer Study Group of Japan (2009 Revised Version). Hepatol Res 40: 686-692, 2010.
21. Liver Cancer Study Group of Japan: The General Rules for the Clinical and Pathological Study of Primary Liver Cancer, 5th edition. Tokyo: Kanehara 2008 (in Japanese).
22. Fink D, Nebel S, Aebi S, Zheng H, Cenni B, Nehmé A, Christen RD and Howell SB: The role of DNA mismatch repair in platinum drug resistance. Cancer Res 56: 4881-4886, 1996. (Pubitemid 26374423)